1 / 8

The JLIGHT Study

The JLIGHT Study Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients. Reference

abia
Télécharger la présentation

The JLIGHT Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The JLIGHT Study Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients Reference Iino Y, Hayashi M, Kawamura T, et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res. 2004;27:21–30.

  2. Background Numerous strands of evidence indicate the benefit of angiotensin II receptor antagonists in ameliorating kidney disease, especially proteinuria. Antihypertensive medications such as angiotensin II receptor antagonists may have a protective effect on the kidneys. However, the renoprotective effect of these agents could be higher than the renoprotection achieved secondary to usual blood pressure control. To study this putative observation, Iino et al. compared the renoprotective losartan with amlodipine using proteinuria as an endpoint. Proteinuria plays a key role in the progression of kidney diseases, eventually leading to end-stage renal disease (ESRD). Key excerpts of this study are the focus of this summary.

  3. Aim To compare the effects of the losartan and amlodipine in patients with chronic kidney disease and hypertension.

  4. Methods

  5. Key Results • SBP and DBP were not significantly different between the losartan and amlodipine groups (Fig. 1). • Urinary protein excretion was significantly reduced in the losartan group as compared to amlodipine group (Fig. 2). • Urinary protein excretion, stratified by blood pressure was significantly reduced in the losartan group as compared to amlodipine group.

  6. Conclusions In patients with proteinuric chronic kidney disease and hypertension, losartan effectively reduced proteinuria while amlodipine did not. It is noteworthy that the potency of BP-lowering effect of losartan and amlodipine was same throughout the entire 12-month study period. Losartan is effective in patients with chronic kidney disease, manifesting proteinuria, and hypertension. This renoprotective property may be quantitatively higher than the effects expected due to routine blood pressure control.

More Related